Table 2 Correlation between ERα-36 expression and clinico-pathological features
From: ERα-36 regulates progesterone receptor activity in breast cancer
Variable | ERα-36 low, no. (%) | ERα-36 high, no. (%) | p value | |
|---|---|---|---|---|
Age (years) | Mean (+ SD) | 56.6 (+ 12.3) | 57.9 (+ 12.9) | 0,43† |
Age groups | < 50 years | 32 (33.7%) | 19 (29.2%) | 0.5 |
> 50 years | 63 (66.3%) | 46 (70.8%) | ||
Side | Right | 42 (44.2%) | 30 (46.2%) | 0.8 |
Left | 53 (55.8%) | 35 (53.8%) | ||
T. size | < 2 cm | 41 (43.2%) | 27 (41.5%) | 0.83 |
> 2 cm | 54 (56.8%) | 38 (58.5%) | ||
LN met | Negative | 45 (47.4%) | 31 (47.4%) | 0.9 |
Positive | 50 (52.6%) | 34 (52.3%) | ||
SBR grade | Gr 1 | 13 (13.7%) | 13 (20%) | 0.039†† |
Gr 2 | 50 (52.6%) | 21 (32.3%) | ||
Gr 3 | 32 (33.7%) | 31 (47.7%) | ||
ERα status | Negative | 9 (9.6%) | 5 (7.7%) | 0.7†† |
Positive | 85 (90.4%) | 60 (92.3%) | ||
PR status | Negative | 23 (24.5%) | 17 (26.6%) | 0.7 |
Positive | 71 (75.5%) | 47 (73.4%) | ||
ERα/PR detailed | ERα+/PR+ | 71 (75.5%) | 47 (73.4%) | 0.78†† |
ERα+/PR− | 14 (14.9%) | 12 (18.8%) | ||
ERα−/PR+ | 0 (0.0%) | 0 (0.0%) | ||
ERα−/PR− | 9 (9.6%) | 5 (7.8%) | ||
Her 2 status | Negative | 78 (85.7%) | 51 (83.6%) | 0.7 |
Over-expressed | 13 (14.3%) | 10 (16.4%) | ||